Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Carus
Dundee, Scotland, United Kingdomcarusbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Carus Therapeutics was a biotechnology company primarily focused on the development of novel treatments for Rett Syndrome, a rare genetic neurological disorder. The company's research centered on identifying and developing small molecule activators of the MECP2 protein, which is deficient or dysfunctional in patients with the condition. Spun out from academic research at the University of Dundee, Carus aimed to address the underlying genetic cause of Rett Syndrome rather than just managing symptoms. Despite its specialized focus and support from patient advocacy groups, the company was dissolved in early 2021.
- Therapeutic areas
- Neurology
- Modalities
- Small molecule
- Industry
- Biotech
02
Partnerships
Rett Syndrome Research Trust (RSRT)
Beyond the preview
Go deeper on Carus.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Carus.